Although the mortality of ACS has declined substantially [11], the situation stays critical. It is estimated that 40% of patients who experience a coronary event will have increased risk of death within 5 years but the risk can be 5–6 times higher in individuals who experience a recurrent event [12–14]. The economic burden due to ACS is also quite huge. The cost of one patient in 1 year is estimated to be from US$22528 to US$32345. The majority of the cost is due to hospitalizations [15, 16]. Given its deleterious impact on health economic consequences, it has been required to have evidence-based management for these patients.